Advertisement

Current Treatment Options in Rheumatology

, Volume 4, Issue 4, pp 329–343 | Cite as

Myositis Mimics—a Clinical Approach to a Diagnostic Challenge

  • Sachiko Takahashi
  • Michael NicolleEmail author
Other CTD: Inflammatory Myopathies and Sjögren's (P Basharat, Section Editor)
  • 19 Downloads
Part of the following topical collections:
  1. Topical Collection on Other CTD: Inflammatory Myopathies and Sjogren's

Abstract

Purpose of the Review

Idiopathic inflammatory myopathies (IIMs) encompass a heterogeneous group of disorders generally referred to as myositis. Myositis mimics are common and their overlapping features with IIMs can pose a diagnostic challenge. This review highlights the current knowledge of various myositis mimics, analyzes key distinguishing features from IIMs, and summarizes practical tips in assessing a patient with possible myositis.

Recent Findings

A new classification criteria for IIMs has been proposed by the European League against Rheumatism/American College of Rheumatology in 2017. Advances in medical genetics have expanded the spectrum of hereditary myopathies, and effective treatment has become available for some. Magnetic resonance imaging (MRI), although not without limitations, is more widely used to differentiate myositis mimics from IIMs. In the end, one must consider the clinical gestalt in formulating a diagnosis.

Summary

A good clinical history, examination, and judicious use and interpretation of ancillary tests are key in approaching a patient with possible IIMs. Monitoring treatment response is also paramount, not only as a clue to reconsidering the diagnosis but also to prevent unwanted side effects and symptom exacerbation from steroids.

Keywords

Myositis Idiopathic inflammatory myopathies Mimics 

Notes

Compliance with Ethical Standards

Conflict of Interest

Sachiko Takahashi declares that she has no conflict of interest. Michael Nicolle declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

The authors have not performed any studies involving human or animal subjects in this article.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    •• Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheum. 2017;69:2271–82.  https://doi.org/10.1002/art.40320 This article proposes a new classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.CrossRefGoogle Scholar
  2. 2.
    •• Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14:269–78.  https://doi.org/10.1038/nrrheum.2018.41 This article outlines the historical perspectives of classifying idiopathic inflammatory myopathies; the new 2017 European League Against Rheumatism/American College of Rheumatology classification criteria; and the features of each clinical entities.CrossRefPubMedGoogle Scholar
  3. 3.
    Venance SL. Approach to the patient with hyperCKemia. Continuum (Minneap Minn). 2016;22:1803–14.  https://doi.org/10.1212/01.CON.0000511069.68640.39.CrossRefGoogle Scholar
  4. 4.
    Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:337–45.  https://doi.org/10.1016/j.nmd.2004.02.006.CrossRefPubMedGoogle Scholar
  5. 5.
    Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009;80:1060–8.  https://doi.org/10.1136/jnnp.2008.169375.CrossRefPubMedGoogle Scholar
  6. 6.
    Basharat P, Christopher-Stine L. Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep. 2015;17:12.  https://doi.org/10.1007/s11926-015-0548-6.CrossRefGoogle Scholar
  7. 7.
    Khadilkar SV, Patel BA, Lalkaka JA. Making sense of the clinical spectrum of limb girdle muscular dystrophies. Pract Neurol. 2018;18:201–10.  https://doi.org/10.1136/practneurol-2017-001799.CrossRefPubMedGoogle Scholar
  8. 8.
    Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638–56.  https://doi.org/10.1002/mus.24566.CrossRefPubMedGoogle Scholar
  9. 9.
    Bastian A, Mageriu V, Micu G, Manole E. The growing family of limb-girdle muscular dystrophies: old and newly identified members. Rom J Intern Med. 2015;53:13–26.  https://doi.org/10.1515/rjim-2015-0002.CrossRefPubMedGoogle Scholar
  10. 10.
    Narayanaswami P, Weiss M, Selcen D, David W, Raynor E, Carter G, et al. Evidence-based guideline summary: diagnosis and treatment of limb-girdle and distal dystrophies: report of the guideline development subcommittee of the American Academy of Neurology and the practice issues review panel of the American Association of Neuromuscular & Electrodiagnostic Medicine. Neurology. 2014;83:1453–63.  https://doi.org/10.1212/WNL.0000000000000892.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Stubgen JP, Ras GJ, Schultz CM, Crowther G. Lung and respiratory muscle function in limb girdle muscular dystrophy. Thorax. 1994;49:61–5.  https://doi.org/10.1136/thx.49.1.61.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Marie I, Hachulla E, Chérin P, Dominique S, Hatron P-Y, Hellot M-F, et al. Interstitial lung disease in polymyositis and dermatomyositis: interstitial lung disease in PM/DM. Arthritis Care Res. 2002;47:614–22.  https://doi.org/10.1002/art.10794.CrossRefGoogle Scholar
  13. 13.
    Maurer B, Walker UA. Role of MRI in diagnosis and management of idiopathic inflammatory myopathies. Curr Rheumato Rep [Internet]. 2015;17.  https://doi.org/10.1007/s11926-015-0544-x [cited 2018 Aug 9].
  14. 14.
    Chu ML, Moran E. The limb–girdle muscular dystrophies: is treatment on the horizon? Neurotherapeutics [Internet]. 2018; Available from: http://link.springer.com/10.1007/s13311-018-0648-x [cited 2018 Aug 9].
  15. 15.
    Rastelli E, Montagnese F, Massa R, Schoser B. Towards clinical outcome measures in myotonic dystrophy type 2: a systematic review. Curr Opin Neurol. 2018;1:1.  https://doi.org/10.1097/WCO.0000000000000591.CrossRefGoogle Scholar
  16. 16.
    Meola G, Cardani R. Myotonic dystrophy type 2: an update on clinical aspects, genetic and pathomolecular mechanism. J Neuromuscul Dis. 2015;2:S59–71.  https://doi.org/10.3233/JND-150088 Lochmüller H, editor.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60:657–64.CrossRefGoogle Scholar
  18. 18.
    Heatwole C. Laboratory abnormalities in patients with myotonic dystrophy type 2. Arch Neurol. 2011;68:1180–4.  https://doi.org/10.1001/archneurol.2011.191.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy. Continuum. 2016;22:1916–31.  https://doi.org/10.1212/CON.0000000000000399.CrossRefPubMedGoogle Scholar
  20. 20.
    Morís G, Wood L, FernáNdez-Torrón R, González Coraspe JA, Turner C, Hilton-Jones D, et al. Chronic pain has a strong impact on quality of life in facioscapulohumeral muscular dystrophy: pain and QoL in FSHD. Muscle Nerve. 2018;57:380–7.  https://doi.org/10.1002/mus.25991.CrossRefPubMedGoogle Scholar
  21. 21.
    Lemmers RJ, Miller DG, van der Maarel SM. Facioscapulohumeral Muscular Dystrophy. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle; 1993. [cited 2018 Aug 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1443/.Google Scholar
  22. 22.
    Toscano A, Barca E, Musumeci O. Update on diagnostics of metabolic myopathies. Curr Opin Neurol. 2017;30:553–62.  https://doi.org/10.1097/WCO.0000000000000483.CrossRefPubMedGoogle Scholar
  23. 23.
    Lilleker JB, Keh YS, Roncaroli F, Sharma R, Roberts M. Metabolic myopathies: a practical approach. Pract Neurol. 2018;18:14–26.  https://doi.org/10.1136/practneurol-2017-001708.CrossRefPubMedGoogle Scholar
  24. 24.
    Byrne BJ, Kishnani PS, Case LE, Merlini L, Müller-Felber W, Prasad S, et al. Pompe disease: design, methodology, and early findings from the Pompe Registry. Mol Genet Metab. 2011;103:1–11.  https://doi.org/10.1007/s10557-005-5686-z.CrossRefPubMedGoogle Scholar
  25. 25.
    Angelini C. Spectrum of metabolic myopathies. Biochim Biophys Acta. 1852;2015:615–21.  https://doi.org/10.1016/j.bbadis.2014.06.031.CrossRefGoogle Scholar
  26. 26.
    Ravaglia S, Bini P, Garaghani KS, Danesino C. Ptosis in Pompe disease: common genetic background in infantile and adult series. J Neuroophthalmol. 2010;30:389–90.  https://doi.org/10.1097/WNO.0b013e3181f9a923.CrossRefPubMedGoogle Scholar
  27. 27.
    Kassardjian CD, Engel AG, Sorenson EJ. Electromyographic findings in 37 patients with adult-onset acid maltase deficiency. Muscle Nerve. 2015;51:759–61.  https://doi.org/10.1002/mus.24620.CrossRefPubMedGoogle Scholar
  28. 28.
    van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med. 2010;362:1396–406.  https://doi.org/10.1056/NEJMoa0909859.CrossRefPubMedGoogle Scholar
  29. 29.
    Das AM, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies. J Biomed Biotechnol. 2010;2010:1–19.  https://doi.org/10.1155/2010/340849.CrossRefGoogle Scholar
  30. 30.
    Quinlivan R, Buckley J, James M, Twist A, Ball S, Duno M, et al. McArdle disease: a clinical review. J Neurol Neurosurg Psychiatry. 2010;81:1182–8.  https://doi.org/10.1136/jnnp.2009.195040.CrossRefPubMedGoogle Scholar
  31. 31.
    Milone M, Wong L-J. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110:35–41.  https://doi.org/10.1016/j.ymgme.2013.07.007.CrossRefPubMedGoogle Scholar
  32. 32.
    Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011;63:859–66.CrossRefGoogle Scholar
  33. 33.
    McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:S89–94.  https://doi.org/10.1016/j.amjcard.2006.02.030.CrossRefGoogle Scholar
  34. 34.
    Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:S52–60.  https://doi.org/10.1016/j.amjcard.2005.12.010.CrossRefGoogle Scholar
  35. 35.
    Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.  https://doi.org/10.1007/s10557-005-5686-z.CrossRefPubMedGoogle Scholar
  36. 36.
    Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. 2018;14:215–24.  https://doi.org/10.1080/1744666X.2018.1440206.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165:2671–6.  https://doi.org/10.1001/archinte.165.22.2671.CrossRefPubMedGoogle Scholar
  38. 38.
    Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317–24.  https://doi.org/10.1016/j.ejim.2012.01.004.CrossRefPubMedGoogle Scholar
  39. 39.
    Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62:2757–66.  https://doi.org/10.1002/art.27572.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713–21.  https://doi.org/10.1002/art.30156.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm. 2015;2:e124.  https://doi.org/10.1212/NXI.0000000000000124.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Pereira RMR, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78:41–4.  https://doi.org/10.1016/j.jbspin.2010.02.025.CrossRefPubMedGoogle Scholar
  43. 43.
    Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.CrossRefGoogle Scholar
  44. 44.
    Khaleeli AA, Edwards RH, Gohil K, McPhail G, Rennie MJ, Round J, et al. Corticosteroid myopathy: a clinical and pathological study. Clin Endocrinol. 1983;18:155–66.CrossRefGoogle Scholar
  45. 45.
    Pasnoor M, Barohn RJ, Dimachkie MM. Toxic myopathies. Neurol Clin. 2014;32:647–70.  https://doi.org/10.1016/j.ncl.2014.04.009.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Fernández-Solà J, Junyent JM, Urbano-Márquez A. Alcoholic myopathies. Curr Opin Neurol. 1996;9:400–5.CrossRefGoogle Scholar
  47. 47.
    Halla JT, Fallahi S, Koopman WJ. Penicillamine-induced myositis. Observations and unique features in two patients and review of the literature. Am J Med. 1984;77:719–22.CrossRefGoogle Scholar
  48. 48.
    • Bourgeois-Vionnet J, Joubert B, Bernard E, Sia MA, Pante V, Fabien N, et al. Nivolumab-induced myositis: a case report and a literature review. J Neurol Sci. 2018;387:51–3.  https://doi.org/10.1016/j.jns.2018.01.030 Case report of novel adverse event associated with Nivolimumab, an immune checkpoint inhibitor, utilized in cancer therapy.CrossRefPubMedGoogle Scholar
  49. 49.
    • Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, et al. Neuromuscular complications of immune checkpoint inhibitor therapy: neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018;58:10–22.  https://doi.org/10.1002/mus.26070 Review article of newly discovered immune-mediated neuromuscular disorders (including inflammatory myopathy) associated with immune checkpoint inhibitors.CrossRefGoogle Scholar
  50. 50.
    • Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep [Internet]. 2018;18 [cited 2018 Sep 8] Available from: http://link.springer.com/10.1007/s11910-018-0878-7. Review article of newly discovered immune-mediated neuromuscular disorders (including inflammatory myopathy) associated with immune checkpoint inhibitors.
  51. 51.
    Horak HA, Pourmand R. Endocrine myopathies. Neurol Clin. 2000;18:203–13.CrossRefGoogle Scholar
  52. 52.
    Sindoni A, Rodolico C, Pappalardo MA, Portaro S, Benvenga S. Hypothyroid myopathy: a peculiar clinical presentation of thyroid failure. Review of the literature. Rev Endocr Metab Disord. 2016;17:499–519.  https://doi.org/10.1007/s11154-016-9357-0.CrossRefPubMedGoogle Scholar
  53. 53.
    Scott KR, Simmons Z, Boyer PJ. Hypothyroid myopathy with a strikingly elevated serum creatine kinase level. Muscle Nerve. 2002;26:141–4.  https://doi.org/10.1002/mus.10128.CrossRefPubMedGoogle Scholar
  54. 54.
    Tajima K, Mashita K, Yamane T, Yoshikawa H, Kawamura S, Kang J, et al. Thyrotoxic myopathy associated with subacute thyroiditis. Clin Endocrinol. 1984;20:307–12.  https://doi.org/10.1111/j.1365-2265.1984.tb00087.x.CrossRefGoogle Scholar
  55. 55.
    Li Q, Liu Y, Zhang Q, Tian H, Li J, Li S. Myopathy in hyperthyroidism as a consequence of rapid reduction of thyroid hormone: a case report. Medicine (Baltimore). 2017;96:e7591.  https://doi.org/10.1097/MD.0000000000007591.CrossRefGoogle Scholar
  56. 56.
    Hardiman O, Molloy F, Brett F, Farrell M. Inflammatory myopathy in thyrotoxicosis. Neurology. 1997;48:339–41.CrossRefGoogle Scholar
  57. 57.
    Rodolico C, Toscano A, Benvenga S, Mazzeo A, Bartolone S, Bartolone L, et al. Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism. Thyroid. 1998;8:1033–8.  https://doi.org/10.1089/thy.1998.8.1033.CrossRefPubMedGoogle Scholar
  58. 58.
    Madhu SV, Jain R, Kant S, Prakash V, Kumar V. Myopathy presenting as a sole manifestation of hypothyroidism. J Assoc Physicians India. 2010;58:569–70.PubMedGoogle Scholar
  59. 59.
    Pimstone N, Marine N, Pimstone B. Beta-adrenergic blockade in thyrotoxic myopathy. Lancet. 1968;292:1219–20.  https://doi.org/10.1016/S0140-6736(68)91697-8.CrossRefGoogle Scholar
  60. 60.
    Araki K, Minami Y, Ueda Y, Kashima K. A case of polymyositis associated with chronic thyroiditis presenting as hyperthyroidism. Jpn J Med. 1990;29:46–51.CrossRefGoogle Scholar
  61. 61.
    Couillard P, Wijdicks EFM. Flaccid quadriplegia due to thyrotoxic myopathy. Neurocrit Care. 2014;20:296–7.  https://doi.org/10.1007/s12028-013-9940-0.CrossRefPubMedGoogle Scholar
  62. 62.
    Hajjar K, Hagenacker T. Neuromuscular disorder as initial manifestation of secondary hyperparathyroidism—a case report. Eur J Transl Myol [Internet]. 2017;27 [cited 2018 Jul 28] Available from: http://pagepressjournals.org/index.php/bam/article/view/6100.
  63. 63.
    Subramanian R, Khardori R. Hyperparathyroid crisis manifesting as respiratory and heart failure. Endocr Pract. 1999;5:350–3.  https://doi.org/10.4158/EP.5.6.350.CrossRefPubMedGoogle Scholar
  64. 64.
    Dai CL, Sun ZJ, Zhang X, Qiu MC. Elevated muscle enzymes and muscle biopsy in idiopathic hypoparathyroidism patients. J Endocrinol Investig [Internet]. 2012; [cited 2018 Jul 28]: Available from: http://www.jendocrinolinvest.it/jei/en/abstract.cfm?articolo_id=7679.
  65. 65.
    Policepatil SM, Caplan RH, Dolan M. Hypocalcemic myopathy secondary to hypoparathyroidism. WMJ. 2012;111:173–5.PubMedGoogle Scholar
  66. 66.
    Crum-Cianflone NF. Infection and musculoskeletal conditions: infectious myositis. Best Pract Res Clin Rheumatol. 2006;20:1083–97.  https://doi.org/10.1016/j.berh.2006.08.005.CrossRefPubMedGoogle Scholar
  67. 67.
    Magee H, Goldman RD. Viral myositis in children. Can Fam Physician. 2017;63:365–8.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008;21:473–94.  https://doi.org/10.1128/CMR.00001-08.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Crum-Cianflone NF. Nonbacterial myositis. Curr Infect Dis Rep. 2010;12:374–82.  https://doi.org/10.1007/s11908-010-0118-z.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Johnson RW, Williams FM, Kazi S, Dimachkie MM, Reveille JD. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis Rheum. 2003;49:172–8.  https://doi.org/10.1002/art.11002.CrossRefPubMedGoogle Scholar
  71. 71.
    Virot E, Duclos A, Adelaide L, Miailhes P, Hot A, Ferry T, et al. Autoimmune diseases and HIV infection: a cross-sectional study. Medicine. 2017;96:e5769.  https://doi.org/10.1097/MD.0000000000005769.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Nicolle MW. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum. 2016;22:1978–2005.  https://doi.org/10.1212/CON.0000000000000415.CrossRefPubMedGoogle Scholar
  73. 73.
    Nicolle MW. Myasthenia gravis. Neurologist. 2002;8:2–21.CrossRefGoogle Scholar
  74. 74.
    Paik JJ, Corse AM, Mammen AL. The co-existence of myasthenia gravis in patients with myositis: a case series. Semin Arthritis Rheum. 2014;43:792–6.CrossRefGoogle Scholar
  75. 75.
    Kannaditharayil D, Napier F, Granit V, Bieri P, Herskovitz S. Abnormal spontaneous activity on needle electromyography in myasthenia gravis. Muscle Nerve. 2017;56:E11–2.  https://doi.org/10.1002/mus.25615.CrossRefPubMedGoogle Scholar
  76. 76.
    Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ. Lambert-Eaton myasthenic syndrome. Neurol Clin. 2018;36:379–94.  https://doi.org/10.1016/j.ncl.2018.01.008.CrossRefPubMedGoogle Scholar
  77. 77.
    Titulaer MJ, Lang B, Verschuuren JJ. Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098–107.  https://doi.org/10.1016/S1474-4422(11)70245-9.CrossRefPubMedGoogle Scholar
  78. 78.
    Malik A, Hayat G, Kalia JS, Guzman MA. Idiopathic inflammatory myopathies: clinical approach and management. Front Neurol [Internet]. 2016;7 [cited 2018 Aug 12] Available from: http://journal.frontiersin.org/Article/10.3389/fneur.2016.00064/abstract.
  79. 79.
    Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era: spinal muscular atrophy. Muscle Nerve. 2015;51:157–67.  https://doi.org/10.1002/mus.24497.CrossRefPubMedGoogle Scholar
  80. 80.
    Katiriji B, Al Jaberi MM. Creatine kinase revisited. J Clin Neuromuscul Dis. 2001;2:158–64.CrossRefGoogle Scholar
  81. 81.
    Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171.  https://doi.org/10.4103/2152-7806.169561.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Dumitru D, Amato AA, Zwarts MJ, editors. Electrodiagnostic medicine. 2nd ed. Philadelphia: Hanley & Belfus; 2002.Google Scholar
  83. 83.
    Tai H, Cui L, Guan Y, Liu M, Li X, Shen D, et al. Correlation of creatine kinase levels with clinical features and survival in amyotrophic lateral sclerosis. Front Neurol [Internet]. 2017:8 [cited 2018 Aug 10] Available from: http://journal.frontiersin.org/article/10.3389/fneur.2017.00322/full.
  84. 84.
    Finsterer J, Aliyev R. Fasciculations in human hereditary disease. Acta Neurol Belg. 2015;115:91–5.  https://doi.org/10.1007/s13760-014-0335-6.CrossRefPubMedGoogle Scholar
  85. 85.
    Michelle EH, Mammen AL. Myositis mimics. Curr Rheumatol Rep [Internet]. 2015;17 [cited 2018 Aug 12] Available from: http://link.springer.com/10.1007/s11926-015-0541-0.
  86. 86.
    Huber AM. Juvenile idiopathic inflammatory myopathies. Pediatr Clin N Am. 2018;65:739–56.  https://doi.org/10.1016/j.pcl.2018.04.006.CrossRefGoogle Scholar
  87. 87.
    Hilton-Jones D. Myositis mimics: how to recognize them. Curr Opin Rheumatol. 2014;26:663–70.  https://doi.org/10.1097/BOR.0000000000000101.CrossRefPubMedGoogle Scholar
  88. 88.
    Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24:193–207.  https://doi.org/10.1016/j.pmr.2012.08.017.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.London Health Sciences CentreUniversity HospitalLondonCanada
  2. 2.Division of Neurology, Department of Clinical Neurosciences, Schulich School of Medicine and DentistryWestern UniversityLondonCanada

Personalised recommendations